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Summary
 
Ex vivo culture of human hematopoietic cells is a crucial component of many therapeutic ap-
plications. Although current culture conditions have been optimized using quantitative in vitro
progenitor assays, knowledge of the conditions that permit maintenance of primitive human
repopulating cells is lacking. We report that primitive human cells capable of repopulating
nonobese diabetic (NOD)/severe combined immunodeficiency (SCID) mice (SCID-repopu-
lating cells; SRC) can be maintained and/or modestly increased after culture of CD34
 
1
 
CD38
 
2
 
cord blood cells in serum-free conditions. Quantitative analysis demonstrated a 4- and 10-fold
increase in the number of CD34
 
1
 
CD38
 
2
 
 cells and colony-forming cells, respectively, as well as
a 2- to 4-fold increase in SRC after 4 d of culture. However, after 9 d of culture, all SRC were
lost, despite further increases in total cells, CFC content, and CD34
 
1
 
 cells. These studies indi-
cate that caution must be exercised in extending the duration of ex vivo cultures used for trans-
plantation, and demonstrate the importance of the SRC assay in the development of culture
conditions that support primitive cells.
 
E
 
x vivo culture is a crucial component of several clinical
applications currently in development including gene
therapy, tumor cell purging, and stem/progenitor cell ex-
pansion (1, 2). Ideally, each of these therapies requires
maintenance or expansion of repopulating cells without in-
duction of differentiation. Clinical transplantation studies
have demonstrated that human hematopoietic cells can be
cultured ex vivo with or without stroma and still retain the
capacity to engraft human recipients, although it is not
known if their number is reduced (3–5). Moreover, all of
these studies involve autologous transplantation, making it
difficult to determine whether long-term repopulation was
derived from cultured cells or from surviving endogenous
stem cells. Although clinical gene marking studies could
address the question of stem cell maintenance in an autolo-
gous setting, conclusive evidence that engraftment was de-
rived from a pluripotent stem cell is still lacking (6, 7). It
appears that the ex vivo culture conditions for gene transfer
may not induce the cycling of repopulating cells (as re-
quired for retrovirus-mediated gene transfer; reference 8),
or they may induce stem cells to differentiate resulting in
the loss of their repopulating capacity (2).
Typically, ex vivo cultures are initiated from mononu-
clear cells or purified CD34
 
1
 
 cells (1), although in some
cases, highly purified CD34
 
1
 
CD38
 
2
 
 and CD34
 
1
 
Thy-1
 
1
 
cells have been used (9–11). Whether primitive cells are ac-
tually expanded during ex vivo culture is controversial be-
cause different assays and culture conditions have been used
in different studies (10, 12–14). It has recently been dem-
onstrated that highly purified subfractions of CD34
 
1
 
 cells
possess the greatest proliferative potential, resulting in a
large expansion of colony-forming cells (CFC), while long-
term culture initiating cells (LTC-IC) show either a slight
reduction (15) or moderate increase (13). Although these in
vitro assays provide an essential quantitative assessment of
the functional properties of the expanded cells, they do not
evaluate repopulation capacity.
Recently, we have identified a novel human hematopoi-
etic cell, termed the SCID repopulating cell (SRC), that is
capable of extensive proliferation and multilineage repopu-
lation of the bone marrow of nonobese diabetic (NOD)/
SCID mice. Using cell purification and retroviral gene mark-
ing, the SRC were found to be biologically distinct from
CFC and most LTC-IC (16, 17). The SRC were found
exclusively in the CD34
 
1
 
CD38
 
2
 
 cell fraction and, under
our conditions, were poorly transduced with retroviral vec-
tors relative to CFC and LTC-IC. A quantitative assay for
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SRC was developed using limiting dilution analysis (18),
enabling us to determine that there is 1 SRC in 617
CD34
 
1
 
CD38
 
2
 
 cells (17). Using this quantitative assay, we
have compared the effect of ex vivo culture on SRC, CFC,
mononuclear cells, as well as CD34
 
1
 
CD38
 
2
 
 and CD34
 
1
 
CD38
 
1
 
 cell content.
 
Materials and Methods
 
Cell Purification.
 
Samples of cord blood (CB) were obtained
from placental and umbilical tissues and the mononuclear cells
were collected on Ficoll (Pharmacia, Uppsala, Sweden). CD34
 
1
 
CD38
 
2
 
 and CD34
 
1
 
CD38
 
1
 
 cells were collected using our stan-
dard protocol (17). In brief, CB cells were first enriched for
CD34
 
1
 
 cells by negative selection using the StemSep device
(Stem Cell Technologies Inc., Vancouver, Canada). These cell
fractions were further purified on a FACStar Plus
 
Ò
 
 (Becton Dickin-
son, San Jose, CA), based on CD34 and CD38 expression using
similar sorting gates shown previously (17).
 
Clonogenic Progenitor Assays.
 
Human clonogenic progenitors
were assayed under standard conditions (16), except that 10%
5637-conditioned medium was included.
 
Liquid Suspension Cultures.
 
CD34
 
1
 
CD38
 
2
 
 and CD34
 
1
 
CD38
 
1
 
cells were incubated in 50 
 
m
 
l of IMDM supplemented with 1%
BSA (Stem Cell Technologies Inc.), 5 
 
m
 
g/ml of human insulin
(Humulin R, Lilly, Canada), 100 
 
m
 
g/ml of human transferrin
(GIBCO BRL, Burlington, Canada), 10 
 
m
 
g/ml of low density li-
poproteins (Sigma Chemical Co., St. Louis), 10
 
2
 
4
 
 M 
 
b
 
-mercap-
toethanol and growth factors (GF). The GF cocktail was used at
final concentrations of 300 ng/ml of stem cell factor (Amgen Bio-
logicals, Thousand Oaks, CA) and Flt-3 (Immunex, Seattle, WA),
50 ng/ml of granulocytic CSF (Amgen Biologicals), and 10 ng/
ml of IL-3 (Amgen Biologicals) and IL-6 (Amgen Biologicals).
Cells were cultured in flat-bottomed suspension wells of 96-well
plates (Nunc, Burlington, Canada), incubated for 4 and 9 d at
37
 
8
 
C and 5% CO
 
2
 
, and 50 
 
m
 
l of fresh GF cocktail was added to
each well every other day.
 
Transplantation of Purified Cells into NOD/SCID Mice.
 
Cells were
transplanted into NOD/LtSz-scid/scid (NOD/SCID) mice ac-
cording to our standard protocol (16). In all cases, cells were
cotransplanted with nonrepopulating CD34
 
2
 
Lin
 
1
 
 cells as acces-
sory cells. The transplanted mice received alternate day intraperi-
toneal injections of human cytokines (human stem cell factor, 10
 
m
 
g, human IL-3 and human GM-CSF, 6 
 
m
 
g; provided by I. Mc-
Niece, Amgen Biologicals). Mice were killed 8–10 wk after
transplantation, and bone marrow (BM) cells were collected from
femurs, tibiae, and iliac crests.
 
Limiting Dilution Analysis.
 
High molecular weight DNA was
isolated from the BM of transplanted mice and the number of
human cells was quantified by probing with a human chromo-
some 17–specific 
 
a
 
-satellite probe as previously described (19). The
frequency of SRC was determined by limiting dilution analysis as
described previously (17, 18). In brief, a transplanted mouse was
scored as positive (engrafted) if any human cells were detectable in
the murine BM by Southern blot analysis. The data from several
limiting dilution experiments were pooled and analyzed by applying
Poisson statistics to the single-hit model. The frequency of SRC
was calculated using the maximum likelihood estimator (17, 18).
 
Flow Cytometric Analysis of Engrafted NOD/SCID Mice.
 
BM of
engrafted mice was analyzed by flow cytometric analysis using the
FACScan
 
Ò
 
 as described previously (17, 20). The antibody com-
binations used were CD14 and CD20 conjugated to FITC, CD33
and CD19, conjugated to PE, and CD45 was conjugated to peri-
dinin chlorophyll protein. For each mouse analyzed, an aliquot of
cells was also stained with mouse IgG conjugated to FITC, PE,
and peridinin chlorophyll as isotype controls.
 
Results
 
Measurement of the Proliferation and Differentiation of Ex
Vivo Cultures Initiated with Human CD34
 
1
 
CD38
 
2
 
 and CD34
 
1
 
CD38
 
1
 
 Cells.
 
The proliferative capacity of CD34
 
1
 
CD38
 
2
 
and CD34
 
1
 
CD38
 
1
 
 cells were determined by comparing
the number of cells obtained after 4 and 9 d of culture to
those originally seeded (Fig.1). The purified cells were in-
cubated in serum-free media with the addition of growth
factors based on a cocktail previously shown to expand
LTC-IC 30–50-fold in 10–21 d from an initial inoculum
of CD34
 
1
 
CD38
 
2
 
 cells (13). The number of cells in the
CD34
 
1
 
CD38
 
2
 
 wells increased by an average of 4-fold,
whereas the CD34
 
1
 
CD38
 
1
 
 wells increased by more than
16-fold by day 4 (Fig. 1). By day 9, the CD34
 
1
 
CD38
 
2
 
wells increased by 8-fold, whereas the CD34
 
1
 
CD38
 
1
 
 wells
had expanded by 22-fold compared to day 0.
To determine the maintenance of the CD34
 
1
 
CD38
 
2
 
and CD34
 
1
 
CD38
 
1
 
 phenotypes after 4 and 9 d of culture,
individual wells were analyzed by flow cytometry (Fig. 2).
The vast majority of cells obtained after 4 d of culture in
the CD34
 
1
 
CD38
 
2
 
 wells maintained the same phenotype.
However, by day 9, no CD34
 
1
 
CD38
 
2
 
 cells remained and
all of the cells had begun to differentiate, as evidenced by
the large number of CD34
 
1
 
CD38
 
1
 
 cells. A similar pattern
was seen in CD34
 
1
 
CD38
 
1
 
 wells; at day 4 most of the cells
retained the same phenotype, whereas at day 9 extensive
differentiation had occurred with the majority of cells los-
ing both CD34 and CD38 expression.
To determine the effect of in vitro culture on the clono-
genic progenitors present in the CD34
 
1
 
CD38
 
2
 
 and CD34
 
1
Figure 1. Increase in cell number after in vitro culture of CD341
CD382 and CD341CD381 cells. Purified cells were counted and seeded
(25–2,000) in wells containing serum free media (day 0). Cells were har-
vested from individual wells after 4 and 9 d, counted, and the mean fold
increase in absolute cell number of CD341CD382 ( solid bar) and
CD341CD381 (shaded bar) cells was calculated. 
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CD38
 
1
 
 cell fractions, plating assays were performed at day
0, 4, and 9 (Table 1). Initially, both the CD34
 
1
 
CD38
 
2
 
 and
CD34
 
1
 
CD38
 
1
 
 cells had a high plating efficiency (PEf); 1
in 3.3 and 1 in 3.4 cells gave rise to CFC, respectively. After
4 d of culture, the PE of the CD34
 
1
 
CD38
 
2
 
 wells increased
to 1 in 1.1, whereas the CD34
 
1
 
CD38
 
1
 
 had decreased
slightly to 1 in 4.6. After 9 d, the PE of the CD34
 
1
 
CD38
 
2
 
wells had decreased to 1 in 4.5 cells, whereas the CD34
 
1
 
CD38
 
1
 
 wells had decreased even further to 1 in 12.2. Overall,
much higher numbers of progenitors were recovered from
CD34
 
1
 
CD38
 
1
 
 wells than the CD34
 
1
 
CD38
 
2
 
 wells. More-
over, the total number of clonogenic progenitors contin-
ued to increase between 4 and 9 d CD34
 
1
 
CD38
 
1
 
 wells,
whereas the fold increase was less in the CD34
 
1
 
CD38
 
2
 
wells by day 9.
 
Quantitative Analysis of SRC After Ex Vivo Culture.
 
We
have demonstrated through limiting dilution analysis that
SRC are found exclusively in the CD341CD382 fraction
at a frequency of 1 in 617 cells (17). In the present study,
we used the quantitative SRC assay to measure the number
of SRC present in the wells at days 0, 4, and 9 of ex vivo
culture. At day 0, wells were seeded with 500–1,000
CD341CD382 cells. The contents of each well at day 4 and
9 were either transplanted into one NOD/SCID mouse or
divided into three or eight equally sized aliquots before in-
jection into NOD/SCID mice. Human cell engraftment
was determined 6–8 wk later to determine whether an SRC
had been present in the well. The results of one representa-
tive experiment are shown in Fig. 3 A. In this experiment,
five wells were initially seeded with 500 CD341CD382
cells. The total cell number increased fourfold to z2,200
cells/well after 4 d in culture. The mouse transplanted with
the entire contents of one well was engrafted with human
cells. Surprisingly, two out of three mice transplanted with
Figure 2. Analysis of CD34 and CD38 expression of highly purified populations before and after in vitro culture. A representative experiment (n 5 3)
of CD34 and CD38 cell surface expression performed on initially purified CD341CD382 and CD341CD381 cells, and purified cells after 4 and 9 d of
culture in serum-free conditions. The entire contents of individual wells was collected at 4 and 9 d (5,000–9,000 cells), stained with monoclonal antibod-
ies, and analyzed using flow cytometric analysis.
Table 1. Effect of Ex Vivo Culture on the Frequency and
Number of Clonogenic Progenitors Present in the CD341CD382
and CD341CD381Cell Fractions
Day 0 Day 4 Day 9
Plating efficiency
CD341CD382 1 in 3.3 6 0.6 1 in 1.1 6 0.2 1 in 4.5 6 1.5
CD341CD381 1 in 3.4 6 0.7 1 in 4.6 6 0.7 1 in 12.2 6 4.2
Fold increase in CFC
CD341CD382 15.4 3 66.6 8.2 3 62.1
CD341CD381 24.8 3 618.4 32.2 3 66.9
An aliquot of 200–1,000 CD341CD382 or CD341CD381 cells
were plated in progenitor cell assays at the initiation of ex vivo cultures
(day 0). Similar cell doses were plated from wells harvested after 4 and 9 d
of culture. The plating efficiency (mean 6 SD) was calculated by divid-
ing the number of CFC detected over the number of cells plated (n 5
4). The total number of CFC per well was determined taking into ac-
count the total number of cells present in each well, and the fold in-
crease is relative to the input number of CFC at day 0 (mean 6 SD; n 5 4).622 Expansion of Human Hematopoietic Repopulating Cells
730 expanded cells and two out of eight mice transplanted
with only 275 expanded cells were also engrafted (Fig. 3
A). None of the mice transplanted with cells that had been
expanded for 9 d were engrafted, despite the injection of
16-fold more cells compared to the day-4 expanded cul-
tures (4,500 versus 275, respectively). Fig. 3 B summarizes
the level of engraftment in 81 NOD/SCID mice trans-
planted with expanded CD341CD382 cells, at different
doses, from 10 CB samples cultured for 4 d. The frequency
of SRC in the ex vivo–cultured cell populations was calcu-
lated from this data to be 1 SRC in 668 expanded cells
(range 1 in 427 to 1 in 1,043). This frequency is similar to
that in CD341CD382 cells before expansion (1 in 617; ref-
erence 17). Since the absolute number of cells increased
fourfold after 4-d, and there was no significant change in
the frequency of SRC, these results indicate a fourfold in-
crease in the absolute number of repopulating cells.
Expanded SRC Give Rise to Multilineage Differentiation.
To determine whether expanded SRC possessed the same
in vivo proliferative and differentiative capacity as uncul-
tured SRC, BM samples of engrafted mice were analyzed
by multiparameter flow cytometry. A representative analy-
sis of an NOD/SCID mouse transplanted with 1,200 cells
expanded from 400 CD341CD382 cells is shown (Fig. 4).
Figure 3. Quantitative analysis of SRC after ex vivo culture. (A) Rep-
resentative Southern blot analysis of individual NOD/SCID mice trans-
planted with expanded cells from replicate wells at days 4 and 9. Lane 1
represents one mouse transplanted with the contents of one well contain-
ing 2,200 expanded cells, lanes 2–4 represent three individual mice trans-
planted with 730 expanded cells recovered from one well, lanes 5–12 rep-
resent eight mice transplanted with 275 expanded cells recovered from
one well, all at day 4. At day 9, two mice were transplanted with 4,500
and 1,250 expanded cells (lanes 13–14 and 15–16, respectively). DNA
was extracted from the murine BM 8 wk after transplant and hybridized
with a human chromosome 17–specific a-satellite probe. (B) Summary of
the level of human cell engraftment in the BM of 81 mice transplanted
with expanded CD341CD382 cells at 4 d from 10 CB samples.
Figure 4. Multilineage differentiation of human CD341CD382 cells in
NOD/SCID mice after 4 d of ex vivo culture. A representative mouse
was transplanted with 1,200 expanded CD341CD382 CB cells after 4 d
of ex vivo culture. Mouse BM was extracted 8 wk after transplant into
NOD/SCID mice and analyzed by multiparameter flow cytometry. (A)
Histogram of CD45 (human-specific panleukocyte marker) expression in-
dicating that 0.4% of the cells present in the murine BM are human. Sub-
sequent analysis of lineage markers was done on CD451 cells within gate
R1. (B) Isotype control for nonspecific IgG staining of mouse BM. (C–F)
Analysis for the presence of human B cell lineage cells using pan–B cell
marker CD19 (C) and mature B cell marker CD20 (D), and for the pres-
ence of human myeloid cells expressing myeloid marker CD33 (E) and
monocytic marker CD14 (F). Isotype control for lineage markers is indi-
cated by shaded regions of histogram.623 Bhatia et al. Brief Definitive Report
The BM of this mouse contained 0.4% human cells as de-
tected by expression of CD45, a human-specific panleuko-
cyte marker (Fig. 4 A). Human CD451 cells were gated
(region R1 in Fig. 4 A) and these cells were further ana-
lyzed for their expression of lineage-specific antigens. The
isotype control is shown in Fig. 4 B. B lymphoid cells were
present in the murine BM as shown by staining for CD19
and CD20 (Fig. 4, C and D). Fig. 4, E and F demonstrate
the presence of myeloid cells (CD331) and mature mono-
cytes (CD141). This engraftment pattern of mice trans-
planted with expanded CD341CD382 cells is similar to
that observed after transplantation of unsorted CB cells (20)
and of purified CD341CD382 cells (17) demonstrating that
in vitro cultured SRC still possess extensive proliferative
and differentiative capacity.
Discussion
The recently developed SRC assay provides a method to
identify and characterize human repopulating cells and the
factors that govern their developmental program (21). This
report provides the first demonstration that primitive hu-
man repopulating cells can be maintained and even mod-
estly expanded during ex vivo serum-free culture using a
cocktail of cytokines. By quantitative analysis, we found
that the number of SRC increased fourfold after 4 d in cul-
ture concomitant with increases in the total cellularity, and
in the numbers of CFC and CD341CD382 cells. Despite
even greater increases in the total number of cells, CD341
cells, and CFC, no SRC were detected when cells were
cultured for 9 d. Others have shown continued increases in
the number of LTC-IC for up to 21 d of culture (13). This
dissociation between SRC and in vitro progenitors is con-
sistent with our earlier results from gene marking and cell
purification experiments indicating that SRC are distinct
from and more primitive than CFC and most LTC-IC as-
sayed in 5-wk stromal cultures (16, 17). Thus, the SRC as-
say will play an important role in identifying factors that
cause SRC to proliferate without inducing differentiation
and loss of repopulating activity and in the design of meth-
ods to transduce primitive human cells for stem cell gene
therapy.
All prior studies aimed at developing clinical applications
have used surrogate assays to optimize the conditions for ex
vivo cultures including quantification of the number of
CD341 cells, CFC, or LTC-IC (12, 13, 22). Most condi-
tions result in marked expansion of CFC and CD341 cells
(1, 12, 23), with smaller increases in the number of more
primitive cells such as LTC-IC and extended LTC-IC (13,
24). Some studies have shown a decline in LTC-IC during
10 d of culture, probably because assay methods or culture
conditions differ (15). Our results indicate that total cellu-
larity, CFC content, and the number of CD341 cells do
not correlate with the repopulating potential of cultured
cells. Moreover, the more mature CD341CD381 popula-
tion, which has been previously shown to be devoid of re-
populating cells (17), had a higher proliferative capacity
with respect to both total cellularity and CFC number
compared to cultures initiated with CD341CD382 cells af-
ter 4 and 9 d of in vitro culture. Although we have shown
that only a fraction of CD341CD382 cells have SRC ac-
tivity, this combination of cell-surface markers seemed to
provide good correlation with repopulating potential. The
number of CD341CD382 cells increased by four- to five-
fold during the first 4 d of culture, whereas all the cells had
differentiated by 9 d, consistent with the loss of SRC. We
conclude that the SRC assay will play an important role in
the development of clinical methods for ex vivo expansion.
We thank I. McNiece at Amgen Biologicals for cytokines, L. McWhirter for providing cord blood speci-
mens, and members of the laboratory for critically reviewing the manuscript.
Supported by grants from the Medical Research Council of Canada (J.E. Dick), the National Cancer Insti-
tute of Canada with funds from the Canadian Cancer Society and the Canadian Genetic Diseases Network
of the National Centers of Excellence (J.E. Dick), a Research Scientist award from the National Cancer In-
stitute of Canada (J.E. Dick), a Medical Research Council of Canada Scientist award (J.E. Dick), postdoc-
toral fellowships from the National Cancer Institute of Canada (M. Bhatia), the Leukemia Research Fund of
Canada and the Medical Research Council of Canada (J.C.Y. Wang), the Deutsche Krebshilfe (U. Kapp),
and the Human Frontier Science Organization Program and the French Cancer Research Association (D.
Bonnet).
Address correspondence to Dr. John E. Dick, Department of Genetics, Research Institute, Hospital for Sick
Children, 555 University Ave., Toronto, Ontario, Canada, M5G 1X8. Phone: 416-813-6354; FAX: 416-
813-4931; E-mail: dick@sickkids.on.ca
Received for publication 1 May 1997 and in revised form 13 June 1997.
References
1. Moore, M.A. 1995. Expansion of myeloid stem cells in cul-
ture. Semin. Hematol. 32:183–200.
2. Williams, D.A. 1993. Ex vivo expansion of hematopoietic
stem and progenitor cells–robbing Peter to pay Paul? Blood.
81:3169–3172.
3. Brugger, W., S. Heimfeld, R.J. Berenson, R. Mertelsmann,
and L. Kanz. 1995. Reconstitution of hematopoiesis after high-
dose chemotherapy by autologous progenitor cells generated624 Expansion of Human Hematopoietic Repopulating Cells
ex vivo. N. Engl. J. Med. 333:283–287.
4. Chang, J., L. Coutinho, G. Morgenstern, J.H. Scarffe, D.
Deakin, C. Harrison, N.G. Testa, and T.M. Dexter. 1986.
Reconstitution of haemopoietic system with autologous mar-
row taken during relapse of acute myeloblastic leukaemia and
grown in long-term culture. Lancet. 1:294–295.
5. Barnett, M.J., C.J. Eaves, G.L. Phillips, R.D. Gascoyne, D.E.
Hogge, D.E. Horsman, R.K. Humphries, H.G. Klingemann,
P.M. Lansdorp, and S.H. Nantel. 1994. Autografting with
cultured marrow in chronic myeloid leukemia: results of a pi-
lot study. Blood. 84:724–732.
6. Brenner, M.K. 1996. Gene transfer to hematopoietic cells. N.
Engl. J. Med. 335:337–339.
7. Kohn, D.B., K.I. Weinberg, J.A. Nolta, L.N. Heiss, C. Le-
narsky, G.M. Crooks, M.E. Hanley, G. Annett, J.S. Brooks,
A. el-Khoureiy, et al. 1995. Engraftment of gene-modified
umbilical cord blood cells in neonates with adenosine deami-
nase deficiency. Nat. Med. 1:1017–1023.
8. Mulligan, R.C. 1993. The basic science of gene therapy. Sci-
ence (Wash. DC). 260:926–932.
9. Petzer, A.L., P.W. Zandstra, J.M. Piret, and C.J. Eaves. 1996.
Differential cytokine effects on primitive (CD341CD382)
human hematopoietic cells: novel responses to Flt3-ligand and
thrombopoietin. J. Exp. Med. 183:2551–2558.
10. Hao, Q., F.T. Thiemann, D. Peterson, E.M. Smogorzewska,
and G.M. Crooks. 1996. Extended long-term culture reveals
a highly quiescent and primitive human hematopoietic pro-
genitor population. Blood. 88:3306–3313.
11. Lansdorp, P.M., and W. Dragowska. 1992. Long-term eryth-
ropoiesis from constant numbers of CD341 cells in serum-
free cultures initiated with highly purified progenitor cells from
human bone marrow. J. Exp. Med. 175:1501–1509.
12. Kobayashi, M., J.H. Laver, T. Kato, H. Miyazaki, and M.
Ogawa. 1996. Thrombopoietin supports proliferation of hu-
man primitive hematopoietic cells in synergy with steel factor
and/or interleukin-3. Blood. 88:429–436.
13. Petzer, A.L., D.E. Hogge, P.M. Landsdorp, D.S. Reid, and
C.J. Eaves. 1996. Self-renewal of primitive human hemato-
poietic cells (long-term-culture-initiating cells) in vitro and their
expansion in defined medium. Proc. Natl. Acad. Sci. USA. 93:
1470–1474.
14. Young, J.C., A. Varma, D. DiGiusto, and M.P. Backer. 1996.
Retention of quiescent hematopoietic cells with high prolif-
erative potential during ex vivo stem cell culture. Blood. 87:
545–556.
15. Traycoff, C.M., S.T. Kosak, S. Grigsby, and E.F. Srour.
1995. Evaluation of ex vivo expansion potential of cord
blood and bone marrow hematopoietic progenitor cells using
cell tracking and limiting dilution analysis. Blood. 85:2059–
2068.
16. Larochelle, A., J. Vormoor, H. Hanenberg, J.C.Y. Wang, M.
Bhatia, T. Lapidot, T. Moritz, B. Murdoch, L.X. Xiao, I.
Kato, et al. 1996. Identification of primitive hematopoietic
cells capable of repopulating NOD/SCID mice: implications
for gene therapy. Nat. Med. 2:1329–1337.
17. Bhatia, M., J.C.Y. Wang, U. Kapp, D. Bonnet, and J.E.
Dick. 1997. Purification of primitive human hematopoietic
cells capable of repopulating immunodeficient mice. Proc. Natl.
Acad. Sci. USA. 94:5320–5325.
18. Wang, J.C.Y., M. Doedens, and J.E. Dick. 1997. Primitive
human hematopoietic cells are enriched in cord blood com-
pared to adult bone marrow or mobilized peripherial blood as
measured by the quantitative in vivo SCID-repopulating cell
(SRC) assay. Blood. 89:3919–3925.
19. Lapidot, T., F. Pflumio, M. Doedens, B. Murdoch, D.E.
Williams, and J.E. Dick. 1992. Cytokine stimulation of mul-
tilineage hematopoiesis from immature human cells engrafted
in scid mice. Science (Wash. DC). 255:1137–1141.
20. Vormoor, J., T. Lapidot, F. Pflumio, G. Risdon, B. Patter-
son, H.E. Broxmeyer, and J.E. Dick. 1994. Immature human
cord blood progenitors engraft and proliferate to high levels
in immune-deficient SCID mice. Blood. 83:2489–2497.
21. Dick, J.E. 1996. Normal and leukemic human stem cells as-
sayed in SCID mice. Semin. Immunol. 8:197–206.
22. Hao, Q.L., A.J. Shah, F.T. Thiemann, E.M. Smogorzewska,
and G.M. Crooks. 1995. A functional comparison of CD341
CD382 cells in cord blood and bone marrow. Blood. 86:
3745–3753.
23. Bernstein, I.D., R.G. Andrews, and K.M. Zsebo. 1991. Re-
combinant human stem cell factor enhances the formation of
colonies by CD341lin2cells, and the generation of colony-
forming cell progeny from CD341lin2cells cultured with
interleukin-3, granulocyte colony-stimulating factor, or gran-
ulocyte-macrophage colony-stimulating factor. Blood. 77:2316–
2321.
24. Shah, A.J., E.M. Smogorzewska, C. Hannum, and G.M.
Crooks. 1996. Flt3 ligand induces proliferation of quiescent
human bone marrow CD341CD382 cells and maintains pro-
genitor cells in vitro. Blood. 87:3563–3570.